Deficiency of Transcription Factor SP1 Contributes to Hypertrophic Cardiomyopathy

Fulei Zhang,Huixing Zhou,Jinfeng Xue,Yuemei Zhang,Liping Zhou,Junwei Leng,Guojian Fang,Yuanyuan Liu,Yan Wang,Hongyu Liu,Yahan Wu,Lingbin Qi,Ran Duan,Xiaoyu He,Yan Wang,Yi Liu,Li Li,Jian Yang,Dandan Liang,Yi-Han Chen

DOI: https://doi.org/10.1161/circresaha.123.323272

IF: 23.213

2024-01-11

Circulation Research

Abstract:Circulation Research, Ahead of Print. BACKGROUND:Hypertrophic cardiomyopathy (HCM) is the most prevalent monogenic heart disorder. However, the pathogenesis of HCM, especially its nongenetic mechanisms, remains largely unclear. TFs (transcription factors) are known to be involved in various biological processes including cell growth. We hypothesized that Sp1 (specificity protein 1), the first purified TF in mammals, plays a role in the cardiomyocyte growth and cardiac hypertrophy of HCM.METHODS:Cardiac-specific conditional knockout of Sp1 mice were constructed to investigate the role of SP1 in the heart. The echocardiography, histochemical experiment, and transmission electron microscope were performed to analyze the cardiac phenotypes of cardiac-specific conditional knockout of Sp1 mice. RNA sequencing, chromatin immunoprecipitation sequencing, and adeno-associated virus experiments in vivo were performed to explore the downstream molecules of SP1. To examine the therapeutic effect of SP1 on HCM, an SP1 overexpression vector was constructed and injected into the mutant allele of Myh6 R404Q/+ (Myh6c. 1211C>T) HCM mice. The human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) from a patient with HCM were used to detect the potential therapeutic effects of SP1 in human HCM.RESULTS:The cardiac-specific conditional knockout of Sp1 mice developed a typical HCM phenotype, displaying overt myocardial hypertrophy, interstitial fibrosis, and disordered myofilament. In addition, Sp1 knockdown dramatically increased the cell area of hiPSC-CMs and caused intracellular myofibrillar disorganization, which was similar to the hypertrophic cardiomyocytes of HCM. Mechanistically,Tuft1was identified as the key target gene of SP1. The hypertrophic phenotypes induced by Sp1 knockdown in both hiPSC-CMs and mice could be rescued by TUFT1 (tuftelin 1) overexpression. Furthermore, SP1 overexpression suppressed the development of HCM in the mutant allele of Myh6 R404Q/+ mice and also reversed the hypertrophic phenotype of HCM hiPSC-CMs.CONCLUSIONS:Our study demonstrates that SP1 deficiency leads to HCM. SP1 overexpression exhibits significant therapeutic effects on both HCM mice and HCM hiPSC-CMs, suggesting that SP1 could be a potential intervention target for HCM.

cardiac & cardiovascular systems,peripheral vascular disease,hematology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of transcription factor Sp1 in hypertrophic cardiomyopathy (HCM) and its underlying mechanisms. Specifically, the researchers hypothesized that Sp1 plays an important role in cardiac cell growth and myocardial hypertrophy in HCM, and verified this hypothesis by constructing a mouse model with cardiac - specific conditional knockout of Sp1. In addition, the study also explored the therapeutic effect of Sp1 over - expression on HCM, in the hope of finding new intervention targets for HCM.

### Main research questions:
1. **The role of Sp1 in HCM**: Researchers hope to determine whether Sp1 is involved in the pathogenesis of HCM through the conditional knockout mouse model.
2. **Downstream molecules of Sp1**: Identify the downstream target genes of Sp1, especially those related to HCM, through techniques such as RNA sequencing and chromatin immunoprecipitation sequencing (ChIP - seq).
3. **Therapeutic potential of Sp1 over - expression**: Study whether Sp1 over - expression can reverse the phenotype of HCM, thereby evaluating its potential as a therapeutic target for HCM.

### Research methods:
- **Animal model**: Construct mice with cardiac - specific conditional knockout of Sp1 (Sp1 - CKO), and analyze their cardiac phenotypes through a variety of experimental means (such as echocardiography, histochemical staining, transmission electron microscopy, etc.).
- **Molecular biology techniques**: Use RNA sequencing and ChIP - seq techniques to identify the downstream target genes of Sp1, and analyze the functions of these genes through gene ontology (GO) analysis.
- **Treatment experiments**: Construct Sp1 over - expression vectors, inject them into HCM mice carrying the Myh6 R404Q mutation and human - induced pluripotent stem cell - derived cardiomyocytes (hiPSC - CMs), and evaluate their therapeutic effects.

### Key findings:
- **Sp1 knockout leads to HCM phenotype**: Sp1 - CKO mice showed obvious myocardial hypertrophy, interstitial fibrosis, and myofilament disarray.
- **Tuft1 is a key downstream molecule of Sp1**: Through ChIP - seq and RNA sequencing, Tuft1 was identified as a direct target gene of Sp1, and its expression decreased significantly after Sp1 knockout.
- **Sp1 over - expression has a therapeutic effect**: Sp1 over - expression can reverse the HCM phenotype caused by Sp1 knockout, and also shows a significant therapeutic effect in mice carrying the Myh6 R404Q mutation and hiPSC - CMs.

### Conclusion:
The research results indicate that Sp1 plays a key role in the pathogenesis of HCM, and its over - expression may become a potential therapeutic strategy for HCM. These findings provide new directions for the prevention and treatment of HCM.